Carter M Suryadevara
Overview
Explore the profile of Carter M Suryadevara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
810
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khan H, Hill T, Suryadevara C, Carter C, Eremiev A, Save A, et al.
Neurosurg Focus
. 2023 Dec;
55(6):E4.
PMID: 38039535
Objective: Controlling length of stay (LOS) reduces rates of nosocomial infections and falls, facilitates earlier return to daily activities, and decreases strain on the healthcare system. Complications following supratentorial tumor...
2.
Boccalatte F, Mina R, Aroldi A, Leone S, Suryadevara C, Placantonakis D, et al.
Cancers (Basel)
. 2022 Oct;
14(20).
PMID: 36291891
Chimeric antigen receptor (CAR) T cells in solid tumors have so far yielded limited results, in terms of therapeutic effects, as compared to the dramatic results observed for hematological malignancies....
3.
Swartz A, Congdon K, Nair S, Li Q, Herndon 2nd J, Suryadevara C, et al.
NPJ Vaccines
. 2021 Jan;
6(1):12.
PMID: 33462231
Personalized cancer vaccines targeting neoantigens arising from somatic missense mutations are currently being evaluated for the treatment of various cancers due to their potential to elicit a multivalent, tumor-specific immune...
4.
Riccione K, He L, Fecci P, Norberg P, Suryadevara C, Swartz A, et al.
Oncoimmunology
. 2018 Dec;
7(12):e1502904.
PMID: 30524899
Despite their promise, tumor-specific peptide vaccines have limited efficacy. CD27 is a costimulatory molecule expressed on CD4 and CD8 T cells that is important in immune activation. Here we determine...
5.
Suryadevara C, Desai R, Farber S, Choi B, Swartz A, Shen S, et al.
Clin Cancer Res
. 2018 Nov;
25(1):358-368.
PMID: 30425092
Purpose: Chimeric antigen receptor (CAR) T cells have shown promise against solid tumors, but their efficacy has been limited, due in part, to immunosuppression by CD4FoxP3 regulatory T cells (Tregs)....
6.
Spino M, Kurz S, Chiriboga L, Serrano J, Zeck B, Sen N, et al.
Clin Cancer Res
. 2018 Nov;
25(4):1261-1271.
PMID: 30397180
Purpose: Isocitrate dehydrogenase ()-mutant glioma is a distinct glioma molecular subtype for which no effective molecularly directed therapy exists. Low-grade gliomas, which are 80%-90% -mutant, have high RNA levels of...
7.
Atik A, Suryadevara C, Schweller R, West J, Healy P, Herndon Ii J, et al.
J Clin Neurosci
. 2018 Jul;
56:163-168.
PMID: 30041899
Convection Enhanced Delivery (CED) infuses therapeutic agents directly into the intracranial area continuously under pressure. The convection improves the distribution of therapeutics such as those aimed at brain tumors. Although...
8.
Suryadevara C, Desai R, Abel M, Riccione K, Batich K, Shen S, et al.
Oncoimmunology
. 2018 Jun;
7(6):e1434464.
PMID: 29872570
Adoptive transfer of T cells expressing chimeric antigen receptors (CARs) is an effective immunotherapy for B-cell malignancies but has failed in some solid tumors clinically. Intracerebral tumors may pose challenges...
9.
Gedeon P, Schaller T, Chitneni S, Choi B, Kuan C, Suryadevara C, et al.
Clin Cancer Res
. 2018 Apr;
24(15):3611-3631.
PMID: 29703821
Conventional therapy for malignant glioma fails to specifically target tumor cells. In contrast, substantial evidence indicates that if appropriately redirected, T cells can precisely eradicate tumors. Here we report the...
10.
Reap E, Suryadevara C, Batich K, Sanchez-Perez L, Archer G, Schmittling R, et al.
Cancer Res
. 2017 Nov;
78(1):256-264.
PMID: 29093005
Median survival for glioblastoma (GBM) remains <15 months. Human cytomegalovirus (CMV) antigens have been identified in GBM but not normal brain, providing an unparalleled opportunity to subvert CMV antigens as...